BELLUS Health Inc.

The business development heads of GSK, Novo Nordisk and Amgen have laid out their views on the state of biopharma, pointing out that dealmaking has not been as sluggish as some players may claim and n

Better-than-expected performances from GSK plc ’s vaccines, HIV and respiratory divisions helped get the firm off to a strong start in the first quarter, as it awaits approval of the first preventati

GSK has added to its recent run of acquisitions and in-licensing deals with the £1.6bn ($2bn) buyout of Bellus Health , a company with a potential best-in-class chronic cough drug in its pipeline. I

The number of players in the chronic cough field is thinning out with Bayer AG deciding to discontinue the development of partner Evotec SE 's eliapixant, sending the price of its fellow German par